Abstract
Poster Presentations
NO CLINICALLY RELEVANT PHARMACOKINETIC INTERACTIONS BETWEEN AMBRISENTAN AND TADALAFIL

https://doi.org/10.1378/chest.134.4_MeetingAbstracts.p161002Get rights and content

Section snippets

Abstract

PURPOSE: Ambrisentan is an oral, once-daily, ETA-selective endothelin receptor antagonist that is approved for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO class II or III symptoms. Tadalafil is an oral, once-daily, phosphodiesterase type 5 (PDE-5) inhibitor currently under investigation for the treatment of PAH. Concomitant use of these two oral, once-daily therapies for PAH may be likely; therefore, this study was designed to assess the potential for

References (0)

Cited by (0)

View full text
Copyright © 2008 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.